Parnell Pharmaceuticals Expands U.S. Footprint with Noble Pharma Acquisition

Introduction

Parnell Pharmaceuticals Holdings, Inc. has made a strategic move by acquiring Noble Pharma, LLC, a U.S.-based manufacturer of sterile injectable products. This $10 million transaction not only solidifies Parnell's manufacturing capabilities but also expands its operational footprint in the growing U.S. veterinary market.

Deal Summary

The acquisition of Noble Pharma marks a pivotal step for Parnell Pharmaceuticals as it looks to enhance its product offerings and operational efficiency. Noble Pharma, known for its expertise in the development and manufacturing of sterile injectables, operates out of a state-of-the-art facility in North Carolina. This facility is expected to increase Parnell's production capacity, thereby meeting the rising demand for veterinary pharmaceuticals.

Mark Parnell, CEO of Parnell Pharmaceuticals, emphasized the significance of this acquisition by stating, “This acquisition is a significant milestone for Parnell as it allows us to scale our operations and meet the increasing needs of our customers.” With this addition, Parnell aims to improve its supply chain efficiencies and offer a broader range of products to its clientele.

Buyer Profile

Parnell Pharmaceuticals Holdings, Inc. is a global player in the veterinary pharmaceutical market, dedicated to developing innovative products aimed at enhancing the health and well-being of companion animals. The company’s focus on advanced product development has positioned it well within the industry.

In recent months, Parnell has been active in the M&A space. Notable transactions include the acquisition of Veterinary Product Labs, which expanded its product line into new therapeutic areas, and a strategic partnership with Pet Health Innovations aimed at enhancing technological advancements in veterinary care. Such moves reflect Parnell’s commitment to growth and innovation within the veterinary sector.

Link to Seller's website: Noble Pharma

Link to Buyer's website: Parnell Pharmaceuticals

Conclusion

For investors and industry stakeholders, Parnell's acquisition of Noble Pharma presents a compelling opportunity to follow the evolving landscape of veterinary pharmaceuticals. As Parnell integrates Noble Pharma's manufacturing prowess into its operations, it stands to improve its market position significantly, catering to the increasing demands of the veterinary market.